Clinical trials: Hypercalcemia
Hypercalcemia, Renal Injury
Exploring Pathogenesis and Treatment of Hypercalcemia Caused by Intramuscular Injection of Paraffinoil
The aim of the study is to characterize paraffin oil induced granulomatous disease. We will investigate pathogenesis and natural history of paraffin disease.
- Conditions
- Hypercalcemia, Renal Injury, Paraffinoma
- Trial name
- NCT04265599
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Herlev Hospital
Idiopathic Infantile Hypercalcemia - Mild Form
The Antibiotic Rifampin to Reduce High Levels of Blood and Urine Calcium in IIH
Idiopathic infantile hypercalcemia(IIH) is a rare,genetic disorder of mineral metabolism. Biallelic loss of functions mutations of CYP24A1, the gene encoding the 24-hydroxylase enzyme that represents the principal pathway for…
- Trial name
- NCT03384121
- Testing
- Rifampin 150 mg, 300 mg capsules and 25 mg/mL oral suspension
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- The Hospital for Sick Children
Parathyroid Carcinoma, Primary Hyperparathyroidism
Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism
To evaluate the efficacy of KHK7580 orally administered up to 24 weeks for hypercalcemia in patient with parathyroid carcinoma or primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after…
- Trial name
- NCT03280264
- Testing
- KHK7580
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Primary Hyperparathyroidism, Hypercalcemia
Differentially Expressed Proteins in Sporadic Parathyroid Tumors
Primary hyperparathyroidism (PHPT) is one of the common endocrine disorders. The major clinical symptoms involve stones, bones, abdominal groans and psychiatric moans.
- Trial name
- NCT01647503
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Breast Cancer, Hypercalcemia of Malignancy
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
The purpose of this study is to determine the potential of denosumab to treat Hypercalcemia of Malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates by lowering…
- Conditions
- Breast Cancer, Hypercalcemia of Malignancy, Colon Cancer, Endocrine Cancer
- Trial name
- NCT00896454
- Testing
- denosumab
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 33 people
- Sponsor
- Amgen
Secondary Hyperparathyroidism, Chronic Kidney Disease
Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)
Secondary Hyperparathyroidism (SHPT) occurs in many patients with kidney disease and leads to bone disease. Active forms of vitamin D, calcitriol and paricalcitol, treat SHPT, but may have different effects on blood calcium.
- Trial name
- PACE (NCT00823303)
- Testing
- Paricalcitol, Calcitriol
- Where
- 4 sites in United States
- Volunteers
- 110 people
- Sponsor
- Washington University School of Medicine
Breast Cancer, Hypercalcemia of Malignancy
Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone.
- Conditions
- Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer, Pain
- Trial name
- NCT00060138
- Testing
- monoclonal antibody CAL, zoledronic acid
- Where
- United States
- Sponsor
- Chugai Pharmaceutical
Breast Cancer, Hypercalcemia of Malignancy
Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer
RATIONALE: Ibandronate and zoledronate may help relieve some of the symptoms caused by bone metastases. It is not yet know whether ibandronate is more effective than zoledronate in treating bone metastases from breast cancer.
- Conditions
- Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer
- Trial name
- NCT00326820
- Testing
- ibandronate sodium, zoledronic acid, Zolendronic Acid
- Where
- 79 sites in United Kingdom
- Volunteers
- 1,404 people
- Sponsor
- Wales Cancer Trials Unit
Hypercalcemia
Search for New Genetic Causes of Hypercalcemia by Massively Parallel Sequencing of a Genes Panel
Hypercalcemia, whether chronic or acute, exposes the patient to potentially serious complications (arrhythmias, nephrolithiasis, nephrocalcinosis, ...).
- Trial name
- HyCaGene (NCT02908542)
- Testing
- genetic analysis with massively parallel sequencing
- Where
- France
- Volunteers
- 185 people
- Sponsor
- University Hospital, Caen
Hyperparathyroidism, Diabetes
Insulin Resistance in Primary Hyperparathyroidism
The aims of this study is to analyse if insulin resistance in primary hyperparathyroidism (pHPT) is normalised after parathyroid adenomectomy and if glucose tolerance test may be useful as a diagnostic tool by predicting…
- Conditions
- Hyperparathyroidism, Diabetes, Hypercalcemia
- Trial name
- IRIPH (NCT02711059)
- Testing
- parathyroidectomy
- Where
- Sweden
- Sponsor
- Karolinska University Hospital
Osteoporosis, Osteopenia
Does Treatment of Hypovitaminosis D Increase Calcium Absorption?
The purpose is to perform a one-year study designed to assess whether treatment of hypovitaminosis D increases intestinal absorption of calcium, subsequent retention of calcium within bone, decreases bone turnover, and favorably…
- Conditions
- Osteoporosis, Osteopenia, Vitamin D Deficiency, Hypoparathyroidism
- Trial name
- NCT00581828
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Hypocalcemia, Hypercalcemia
Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome
Parathyroid hormone (PTH) gland calcium sensing receptor (CASR) regulates PTH secretion. CASR is also expressed in nephron thick ascending limb (TAL).
- Trial name
- NCT01021280
- Where
- Israel
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Soroka University Medical Center
Hypercalcemia of Malignancy, Lung Cancer
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
RATIONALE: Zoledronate may help to relieve some of the symptoms caused by bone metastases. It is not yet known if zoledronate is more effective than no further therapy in relieving symptoms of bone metastases or preventing…
- Conditions
- Hypercalcemia of Malignancy, Lung Cancer, Metastatic Cancer, Pain
- Trial name
- NCT00003884
- Testing
- zoledronic acid, quality-of-life assessment
- Where
- 55 sites in United States
- Volunteers
- 600 people
- Sponsor
- Novartis
Cancer, Hypercalcemia
Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community
Treatment in the home and hospice of long-term care facilities, particularly for non-ambulatory patients, could provide significant advantages for patients and for the region.
- Conditions
- Cancer, Hypercalcemia, Pain
- Trial name
- NCT00126386
- Testing
- Zoledronic acid (Zometa)
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- Alberta Health services
Primary Hyperparathyroidism, Hypercalcemia
Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D
Primary hyperparathyroidism (PHPT) is a common disease that occurs in 1 in 10,000 people every year. In the presence of this condition, the parathyroid glands produce excessive amounts of parathyroid hormone (PTH), which…
- Conditions
- Primary Hyperparathyroidism, Hypercalcemia, Vitamin D Deficiency, Osteoporosis
- Trial name
- NCT01329666
- Testing
- Vitamin D3
- Where
- United States
- Sponsor
- Columbia University
Hyperphosphatemia, Hyperkalemia
Rate of Termination of Premixed Parenteral Nutrition (PN) in Surgical Patients Secondary to High Serum Electrolytes
Introduction: Various commercial premixed parenteral nutrition (PN) solutions have been introduced to clinical practice in 3-compartment large volume bags.
- Conditions
- Hyperphosphatemia, Hyperkalemia, Hypermagnesemia, Hypercalcemia
- Trial name
- NCT04256369
- Testing
- Parenteral Nutrition (PN) Premixed Olimel N9E
- Where
- Saudi Arabia
- Volunteers
- 72 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Osteoporosis, Hypercalcemia of Malignancy
One Week Comparison Study of PTH and PTHrP Infusions
This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over one week in healthy African-American volunteers.
- Conditions
- Osteoporosis, Hypercalcemia of Malignancy, Hyperparathyroidism, Bone Diseases, Endocrine
- Trial name
- NCT01333267
- Testing
- Parathyroid Hormone-related Protein (1-36), parathyroid hormone (1-34), PTH (1-34) and PTHrP (1-36)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Multiple Endocrine Neoplasia
Studies of Inherited Diseases of Metabolism
Diseases of mineral metabolism such as familial multiple endocrine neoplasia type 1 (FMEN1), familial hypocaliuric hypercalcemia (FHH), familial hyperparathyroidism (FH), and pseudohypoparathyroidism (PHP) are known as hereditary…
- Trial name
- NCT00001345
- Where
- United States
- Volunteers
- 969 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Secondary Hyperparathyroidism, End-Stage Renal Disease
Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice
The objective of this study was to observe the safety of paricalcitol utilization in pediatric participants (ages 0 to 16 years old) being treated for secondary hyperparathyroidism (SHPT).
- Trial name
- NCT01134315
- Testing
- Paricalcitol, Calcitriol
- Where
- 18 sites in United States
- Volunteers
- 61 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
End-Stage Renal Disease, Secondary Hyperparathyroidism
A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis
The objective is to evaluate the safety of paricalcitol capsules in pediatric subjects, ages 10 to 16 years old, with Stage 5 chronic kidney disease (kidney failure) receiving peritoneal dialysis or hemodialysis and being treated…
- Trial name
- NCT01382212
- Testing
- paricalcitol
- Volunteers
- 13 people
- Sponsor
- AbbVie (prior sponsor, Abbott)